Peter Michael Vestlev

978 total citations
13 papers, 157 citations indexed

About

Peter Michael Vestlev is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Peter Michael Vestlev has authored 13 papers receiving a total of 157 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Peter Michael Vestlev's work include Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Peter Michael Vestlev is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Peter Michael Vestlev collaborates with scholars based in Denmark, Spain and Netherlands. Peter Michael Vestlev's co-authors include J. Buesa, T. Wagener, Richard Sylvester, A.T. van Oosterom, Andrés Poveda, H.T. Mouridsen, Jaap Verweij, D. Thomas, William P. Steward and Erik Jakobsen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Peter Michael Vestlev

11 papers receiving 152 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Michael Vestlev Denmark 4 111 102 39 26 21 13 157
Sucheta More India 6 69 0.6× 99 1.0× 34 0.9× 7 0.3× 12 0.6× 24 141
Jessica Grosjean France 7 106 1.0× 116 1.1× 12 0.3× 42 1.6× 15 0.7× 12 145
María Rodríguez–Soler Spain 7 75 0.7× 35 0.3× 25 0.6× 11 0.4× 60 2.9× 10 141
Martín Lázaro-Quintela Spain 9 89 0.8× 84 0.8× 22 0.6× 15 0.6× 7 0.3× 20 170
Lionel Uwer France 6 140 1.3× 56 0.5× 38 1.0× 6 0.2× 8 0.4× 14 189
L. Belmont France 7 77 0.7× 73 0.7× 24 0.6× 6 0.2× 21 1.0× 19 154
Jian-qiang Cai China 7 102 0.9× 59 0.6× 41 1.1× 9 0.3× 14 0.7× 9 188
Wafaa Elatre United States 6 85 0.8× 114 1.1× 19 0.5× 38 1.5× 12 0.6× 12 208
Pei Jye Voon Malaysia 7 118 1.1× 127 1.2× 20 0.5× 9 0.3× 9 0.4× 28 199
Hamzeh Albaba Canada 6 113 1.0× 67 0.7× 11 0.3× 7 0.3× 8 0.4× 11 152

Countries citing papers authored by Peter Michael Vestlev

Since Specialization
Citations

This map shows the geographic impact of Peter Michael Vestlev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Michael Vestlev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Michael Vestlev more than expected).

Fields of papers citing papers by Peter Michael Vestlev

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Michael Vestlev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Michael Vestlev. The network helps show where Peter Michael Vestlev may publish in the future.

Co-authorship network of co-authors of Peter Michael Vestlev

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Michael Vestlev. A scholar is included among the top collaborators of Peter Michael Vestlev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Michael Vestlev. Peter Michael Vestlev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Gögenür, Ismail, C. J. Hansen, Lene T. Kirkeby, et al.. (2022). Colorectal cancer-associated SNP rs17042479 is involved in the regulation of NAF1 promoter activity. PLoS ONE. 17(9). e0274033–e0274033. 1 indexed citations
2.
Stenvang, Jan, et al.. (2021). Abstract P077: SCO-101 mediates re-sensitization of irinotecan (SN38) resistant colorectal cancer cells. Molecular Cancer Therapeutics. 20(12_Supplement). P077–P077.
3.
Brems-Eskildsen, Anne Sofie, Søren Linnet, Hella Danø, et al.. (2020). Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer. Acta Oncologica. 60(2). 157–164. 9 indexed citations
4.
Bergmann, Troels K., Tore Bjerregaard Stage, Jan Stenvang, et al.. (2020). Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO‐101 in adult male and female volunteers. Basic & Clinical Pharmacology & Toxicology. 127(4). 329–337. 6 indexed citations
5.
6.
Ejlertsen, Bent, Malgorzata Tuxen, Erik Jakobsen, et al.. (2017). Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for EarlyTOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. Journal of Clinical Oncology. 35(23). 2639–2646. 47 indexed citations
7.
Brems-Eskildsen, Anne Sofie, A.A. Luczak, Peter Michael Vestlev, et al.. (2015). Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients. Repositorio Institucional E-DocUR (Universidad Del Rosario). 23.
8.
9.
Kamby, Claus, Simon Tarp, Anders Mellemgaard, et al.. (2014). Forebyggelse af skeletrelaterede hændelser hos patienter med knoglemetastaser ved solide tumorer. VBN Forskningsportal (Aalborg Universitet). 176(7). 2–5. 2 indexed citations
10.
Kamby, Claus, Simon Tarp, Anders Mellemgaard, et al.. (2014). [Prevention of skeletal related events in patients with bone metastases from solid tumours].. PubMed. 176(8A). V08130525–V08130525. 1 indexed citations
11.
Lassen, Ulrik, Steen Knudsen, Iben Kümler, et al.. (2014). Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial.. Journal of Clinical Oncology. 32(15_suppl). TPS1139–TPS1139. 1 indexed citations
12.
Kamby, Claus, Peter Michael Vestlev, & Henning T. Mouridsen. (1992). Site-Specific Effect of Chemotherapy in Patients with Breast Cancer. Acta Oncologica. 31(2). 225–229. 3 indexed citations
13.
Buesa, J., H.T. Mouridsen, A.T. van Oosterom, et al.. (1991). High-dose DTIC in advanced soft-tissue sarcomas in the adult. Annals of Oncology. 2(4). 307–309. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sucheta More Breakdown of academic impact, for papers by Jessica Grosjean Breakdown of academic impact, for papers by María Rodríguez–Soler Breakdown of academic impact, for papers by Martín Lázaro-Quintela Breakdown of academic impact, for papers by Lionel Uwer Breakdown of academic impact, for papers by L. Belmont Breakdown of academic impact, for papers by Jian-qiang Cai Breakdown of academic impact, for papers by Wafaa Elatre Breakdown of academic impact, for papers by Pei Jye Voon Breakdown of academic impact, for papers by Hamzeh Albaba
Rankless by CCL
2026